CA
NZ
UK
AU
IND
US
USANA Health Sciences, Inc. (NYSE:USNA) released stronger-than-expected quarterly earnings. The health and wellness company reported first-quarter earnings per share (EPS) of $0.73, surpassing analysts’ consensus forecast of $0.70. Revenue also outpaced expectations, coming in at $249.54 million against estimates of $243.08 million. However, year-over-year …
Intuitive Surgical, Inc. (Nasdaq:ISRG) has reported financial results for the first quarter ended March 31, 2025. the results are driven by the demand for robotic-assisted procedures and the adoption of its next-gen da Vinci 5 system powered growth across the board.
Walgreens (NASDAQ:WBA) Boots Alliance has agreed to pay up to $350 million to resolve allegations that it filled millions of unlawful prescriptions for opioids and other controlled substances over more than a decade, the U.S. Department of Justice (DOJ) announced on Friday.
Evotec SE (NASDAQ: EVO) has published its full-year 2024 financial results, along with its strategic roadmap through 2028. Following a comprehensive review process, the company announced a realignment to focus on core areas of scientific and technological expertise within drug discovery and biologics development.
Verve Therapeutics (NASDAQ:VERV) exploded higher Tuesday after releasing encouraging early-stage clinical data for its experimental gene-editing treatment VERVE-102, aimed at treating heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease.
The U.S. Food and Drug Administration (FDA) has approved the VYVGART® Hytrulo prefilled syringe for self-injection, offering a new level of convenience and autonomy for adult patients diagnosed with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, as well as those …
Pharmaceutical giant Novartis (NYSE:NVS) announced on Thursday that it will invest $23 billion over the next five years to significantly expand its U.S. operations, reinforcing its commitment to American drug manufacturing as the industry faces growing uncertainty over potential tariffs.
Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, has announced the completion of enrollment and dosing across multiple cohorts in its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC). This includes …
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has announced the completion of participant enrollment in its Phase 2a clinical trial for LP-310, a liposomal tacrolimus oral rinse designed to treat oral lichen planus (OLP), a condition that currently has no FDA-approved treatments. This trial, which includes …
CureVac N.V. (Nasdaq: CVAC), a biotechnology company focused on mRNA-based medicines, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC. This therapy is an mRNA-based precision immunotherapy designed …
Please wait processing your request...